Victoria’s Secret Has a Secret Weapon (and It’s Called a Poison Pill)

In news that has nothing to do with lace or lingerie, Victoria’s Secret has just adopted a poison pill – and no, this one’s not a metaphor for a failed perfume launch. It’s a classic American boardroom manoeuvre: legally sound, routinely controversial.

The trigger? BBRC International, helmed by Australian retail tycoon Brett Blundy, who’s already nabbed around 13% of the company and fancies pushing that figure up to just under 50%. In response, Victoria’s Secret’s board has declared: not so fast, mate.

For those of us used to the UK’s more shareholder-led regime, this sort of boardroom tactic might raise an eyebrow or two. Here’s what’s going on – and why you’d never see the same play in a UK-listed company.

What Is a Poison Pill?

Imagine telling shareholders, “If this one investor buys too much of us, you lot all get a discount.” That’s essentially a poison pill.

Here’s how it works:

• If a shareholder (other than the board’s new least favourite person) acquires more than a certain percentage of shares – say 15%, as in Victoria’s Secret’s case – everyone else gets to buy more shares at a discount.
• The result? The pesky shareholder’s stake is diluted, and the cost of a takeover shoots up faster than a Mayfair rent review.

It’s a well-worn tactic from the corporate defence playbook. It doesn’t block a takeover outright, but it does make the process significantly more expensive – and often messy enough to put a would-be bidder off entirely.

Do They Work?

In the short term: Yes. They can stop a hostile bid in its tracks, buy the board some breathing space, and force would-be acquirers to negotiate rather than sneak in through the side door.

In the long term: It’s a bit more nuanced. Poison pills are often criticised for doing less to protect shareholder value and more to protect the people sitting around the boardroom table. If a credible buyer with a decent premium gets blocked by one, shareholders can end up wondering whose interests are really being defended.

Effectiveness, in practice, depends on how the move is received. If investors see it as a reasonable line of defence – fine. If they see it as a panic button from a nervous board – not so fine. Either way, it rarely ends the conversation. It just changes the tone of it.

Why This Wouldn’t Wash in the UK

If Victoria’s Secret were listed in London, this entire episode would be firmly off the table. That’s because poison pills are effectively banned under UK takeover rules, thanks to a firm but fair bit of regulation called Rule 21.1 of the Takeover Code.

Nicknamed the frustrating action rule, it says that once a takeover bid is on the horizon – even just a sniff of one – the board of the target company must not take any action that could block or interfere with it, unless they first get shareholder approval.

That means no:

• Issuing new shares to dilute a bidder.
• Selling off prized assets to make the company less attractive.
• Introducing last-minute defensive measures designed to tip the scales.

And it’s not just poison pills that are off-limits. Other US-style tactics – like staggered boards (where only a portion of directors can be replaced at a time) or golden shares (which carry special veto rights) – wouldn’t wash in the UK either.

The UK model is built around a simple principle: shareholders decide. Boards are expected to stay neutral, disclose relevant information, and let the market do its job. No last-minute reshuffles. No hidden clauses. Just a transparent process and a vote.

The US, by contrast, gives boards far more discretion. Since the Delaware Supreme Court’s decision in Moran v. Household International (1985), poison pills have been a legal and regularly used tool. Boards can adopt them without shareholder approval, provided they act reasonably and in good faith – meaning they’re supposed to protect shareholder interests, not just their own jobs.

So, while Victoria’s Secret’s board is playing by the book in the US, the same move in the UK would put them firmly on the wrong side of the Takeover Panel – and likely on the receiving end of swift regulatory pushback.

The Last Word

Whether this poison pill ends up protecting shareholder value or simply keeping management in the driver’s seat remains to be seen. What’s clear is that legal context shapes the tactics available in any M&A situation. In the US, boards hold more cards. In the UK, they hold the microphone while shareholders vote.

Different philosophies. Same goal: control.